From GlobeNewswire:

Ascendis Pharma A/S has introduced its 2024 corporate milestones and Vision 2030, which is the strategic roadmap through 2030. The company aims to achieve blockbuster status for multiple products and expand its engine for future innovation. Highlights include a regulatory review for TransCon PTH, plans for a commercial launch, and preliminary unaudited revenue expectations. The company also aims to expand its global reach and maximize value creation in additional therapeutic areas. Patients, Science, and Passion will continue to guide Ascendis Pharma’s decisions for success. This news will be presented at the J.P. Morgan Healthcare Conference on January 8.



Read more: Ascendis Pharma Introduces Vision 2030